Abstract
Dengue is one of the most significant health problems in tropical and sub-tropical regions throughout the world. Nearly 390 million cases are reported each year. Although a vaccine was recently approved in certain countries, an anti-dengue virus drug is still needed. Fruits and vegetables may be sources of compounds with medicinal properties, such as flavonoids. This study demonstrates the anti-dengue virus activity of the citrus flavanone naringenin, a class of flavonoid. Naringenin prevented infection with four dengue virus serotypes in Huh7.5 cells. Additionally, experiments employing subgenomic RepDV-1 and RepDV-3 replicon systems confirmed the ability of naringenin to inhibit dengue virus replication. Antiviral activity was observed even when naringenin was used to treat Huh7.5 cells 24 h after dengue virus exposure. Finally, naringenin anti-dengue virus activity was demonstrated in primary human monocytes infected with dengue virus sertoype-4, supporting the potential use of naringenin to control dengue virus replication. In conclusion, naringenin is a suitable candidate molecule for the development of specific dengue virus treatments.
Highlights
Using flow cytometry, virus titration and replicon assays, this study demonstrated the ability of naringenin to inhibit the replication of four Dengue virus (DENV) serotypes in Huh7.5 cells
Virus titration and replicon assays, this study demonstrated the ability of naringenin to inhibit the replication of four DENV serotypes in Huh7.5 cells
A naringenin concentration of 311.3 μM inhibited 50% of cell viability (CC50)
Summary
Virus titration and replicon assays, this study demonstrated the ability of naringenin to inhibit the replication of four DENV serotypes in Huh7.5 cells. Results Naringenin inhibits infection with four different DENV serotypes in Huh7.5 cells. These results were similar to those observed with IFN-α2A treatment after infection (Fig. 3) and suggest the ability of naringenin to impair DENV replication and/or virus maturation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
